DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/09/2021 16:30 EST Earnings Call Q3 2021 -- -- --
11/09/2021 -- Results Q3 2021 -5.25 -5.83 10.00%
08/05/2021 16:30 EST Earnings Call Q2 2021 -- -- --
08/05/2021 -- Results Q2 2021 -7.25 -8.67 16.35%
05/06/2021 16:30 EST Earnings Call Q1 2021 -- -- --
05/06/2021 -- Results Q1 2021 -13.25 -17.25 23.19%
03/11/2021 16:30 EST Earnings Call Q4 2020 -- -- --
03/11/2021 -- Results Q4 2020 -27.75 -23.50 -18.09%
*Estimated Date/Time

Earnings

Next Report Date --
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2021
Beat/Miss Upgrade
Return Since -94.78%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
URL https://www.nabriva.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Annual Total Returns Versus Peers

Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-37.40%
0.34%
-75.59%
-9.59%
-81.67%
-75.25%
-87.38%
-7.41%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
3.86%
-14.91%
-21.08%
-68.54%
192.6%
-11.52%
20.96%
-11.39%
31.84%
-5.44%
15.89%
15.19%
27.33%
5.67%
-9.81%
-22.55%
3.02%
--
--
--
--
--
--
--
3.87%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
25.05%
-11.32%
As of March 24, 2023.

Profile

Edit
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
URL https://www.nabriva.com
Investor Relations URL N/A
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NBRV Tweets